Approximately half of patients experience initial progressive disease (PD) exclusively from residual tumor lesions after receiving targeted or PD-1/PD-L1 inhibitor therapies for NSCLC (35, 36). This evidence concerns the gene CD274 and non-small cell lung carcinoma.